INCB160058

Phase 1Small molecule

Incyte

INCB160058 is one of 8 small molecule programs targeting Myeloproliferative Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloproliferative NeoplasmsActive, not recruiting

Myeloproliferative NeoplasmsPhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Myeloproliferative Neoplasms

#DrugCompanyPhaseTrials

Jakafi

Incyte

Phase 2

4 2

Cysteine Hydrochloride

Novartis

Phase 2

1 3

Trexall

Jazz Pharmaceuticals

Phase 2

1 4

Vonjo

SSobi, Inc.

Phase 2

2 5

Talzenna

Pfizer

Phase 1

1 6

Tibsovo

SServier

Phase 1

2 7

INCA033989

Incyte

Phase 1

2 8

INCB160058

Incyte

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Myeloproliferative Neoplasms

NCT06313593

Clinical

Trials by Indication[1]

Adult1 trial

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant

Completed· Incyte logo

Incyte·Phase 1·NCT06213818·137 enrolled

Myeloproliferative Neoplasms1 trial

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms

Active, not recruiting· Incyte logo

Incyte·Phase 1·NCT06313593·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for INCB160058. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCB160058 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCB160058. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Incyte

INCB160058

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Adult1 trial

Myeloproliferative Neoplasms1 trial

References

Drug Info

Quick Facts

Related News